** U.S.-listed shares of China-based drug developer Zai Lab

rise 10.6% to $32 premarket

** Co reports data from early-stage study testing its experimental drug to treat previously treated patients with a type of lung cancer

** Says its drug, ZL-1310, helped either remove all signs of cancer from the body or significantly reduce the size of tumor in 74% of patients with recurrent extensive-stage small cell lung cancer

** ZL-1310 belongs to a class of drugs called antibody-drug conjugates, which are targeted cancer therapies that function like "guided missiles" against tumor cells while sparing healthy ones

** Stock up ~6% so far this year as of last close

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))